Personalized treatment for B-cell blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study uses advanced 3D lab models to test personalized treatments for certain types of blood cancer (CLL, SMZL, HCL). It aims to find better ways to use immunotherapy and combination therapies for each patient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of chronic lymphocytic leukemia (CLL), splenic marginal zone lymphoma (SMZL), or hairy cell leukemia (HCL).
- You must be willing and able to give your own consent to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tiny particles called extracellular vesicles in the blood of people with Hairy Cell Leukemia. Researchers want to understand if these particles can help improve how the disease is managed and followed.
This study collects human samples (like blood or other specimens) to learn more about hairy cell leukemia and other leukemias. It also helps researchers develop new lab-made immune-based medicines for cancer treatment.
This study looks at how cells talk to each other in hairy cell leukemia, a rare blood cancer. It aims to find ways to improve patient care. Participants may be asked to give blood or tissue samples for research.
This study watches the course of hairy cell leukemia (HCL) in different phases—when first diagnosed, after it comes back, or long after successful treatment. The goal is to better understand the disease and plan future care.
This study follows people with certain slow-growing blood cancers (CLL/SLL, LPL/WM, and related conditions) to understand how they progress and what leads to needing treatment. It may help doctors predict changes over time and plan care more effectively.
This trial tests a new type of immunotherapy called CAR-T cells that are specially designed to find and attack your cancer cells. It is for people with certain blood cancers that have not improved with standard treatments, and it may give you another option when others have not worked.
Hear when a new Splenic Marginal Zone Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.